NSAIDs, coumarine and bleeding
519
5. Laporte J-R, Carne X, Vidal X, Moreno V, Juan J. Upper
gastrointestinal bleeding in relation to previous use of
analgesics and non-steroidal anti-inflammatory drugs.
Lancet 1991; 337:85–9.
19. Landefeld S, Beyth RJ. Anticoagulant-related bleeding:
clinical epidemiology, prediction, and prevention. Am J
Med 1993; 95:315–28.
20. Marbet GA, Duckert F, Walter M, Six P, Airenne H.
Interaction study between phenprocoumon and flurbiprofen.
Curr Med Res Opin 1977; 5:26–31.
6. Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE,
Alfredsson L, Koff RS, Shapiro S. Nonsteroidal anti-inflam-
matory drug use in relation to major upper gastrointestinal
bleeding. Clin Pharmacol Ther 1993; 53:485–94.
21. Bernth Petersen P, Husted S, Mortensen A, Andreasen F.
The effect of daily administration of naproxen on the
prothrombin complex activity in patients under long-term
therapy with phenprocoumon. Scand J Rheumatol 1979;
8:54–6.
7. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia
J, Sanz M, Montoro M, Sainz R. Nitrovasodilators, low-dose
aspirin, other nonsteroidal antiinflammatory drugs, and the
risk of upper gastrointestinal bleeding. N Engl J Med 2000;
343:834–9.
22. Angelkort B. Zum Einfluss von Naproxen auf die
thrombozytare Blutstillung und die Antikoagulantien-
Behandlung mit Phenprocoumon. Fortschr Med 1978;
96:1249–51.
8. Kraus SE, Siroky MB, Babayan RK, Krane RJ. Hematuria and
the use of nonsteroidal anti-inflammatory drugs. J Urol 1984;
132:288–90.
23. Michot F, Ajdacic K, Glaus L. A double-blind clinical trial to
determine if an interaction exists between diclofenac sodium
and the oral anticoagulant acenocoumarol (Nicoumalone).
J Int Med Res 1975; 3:153.
9. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary
intracerebral haemorrhage associated with aspirin and non-
steroidal anti-inflammatory drugs: case-control study. BMJ
1999; 318:759–64.
24. Meurice J. Interaction of tiaprofenic acid and acenocou-
marol. Rheumatol 1982; 7:111–17.
10. Vane JR, Botting RM. New insights into the mode of action
25. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use
of nonsteroidal anti-inflammatory drugs and oral anti-
coagulants places elderly persons at high risk for hemor-
rhagic peptic ulcer disease. Arch Intern Med 1993;
153:1665–70.
of anti-inflammatory drugs. Inflamm Res 1995; 44:1–10.
11. Rainsford KD. Profile and mechanisms of gastrointestinal and
other side effects of non steroidal anti-inflammatory drugs
(NSAIDs). Am J Med 1999 (Suppl 6A); 107:27–36.
12. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T,
Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF,
Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM,
Geis GS. Gastrointestinal toxicity with celecoxib vs nonste-
roidal anti-inflammatory drugs for osteoarthritis and rheuma-
toid arthritis. The CLASS study: a randomized controlled trial.
JAMA 2000; 284:1247–55.
26. Knijff-Dutmer EAJ, Schut GA, van de Laar MAFJ: Concomi-
tant coumarin-NSAID therapy and risk for bleeding.
Ann Pharmacother 2003; 37:12–16.
27. Chan TYK, Lui SF, Chumg SY, Luk S, Critchley JAJH. Adverse
interaction between warfarin and indomethacin. Drug Safety
1994; 10:267–9.
28. Chan TYK. Prolongation of prothrombin time with the
use of indomethacin and warfarin. Br J Clin Pract 1997;
51:177–8.
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas
R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg MC,
Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal
toxicity of rofecoxib and naproxen in patients with rheuma-
toid arthritis. N Engl J Med 2000; 343:1520–8.
29. Dennis VC, Thomas BK, Hanlon JE. Potentiation of oral
anticoagulation and hemarthrosis associated with nabu-
metone. Pharmacotherapy 2000; 20:234–9
14. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS.
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on
platelet function in healthy adults: a randomized, controlled
trial. J Clin Pharmacol 2000; 40:124–32.
30. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential
interaction between celecoxib and warfarin. Ann Pharma-
cother 2000; 34:666–7.
31. Mersfelder TL, Stewart LR. Warfarin and celecoxib interac-
15. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S,
Kujubu D, Antes L, Lasseter KC, Quan H, Gertz B, FitzGerald
GA. Effects of specific inhibition of cyclooxygenase-2 on
sodium balance, hemodynamics and vasoactive eicosanoids.
J Pharmacol Exp Therap 1999; 289:735–41.
tion. Ann Pharmacother 2000; 34:325–7.
32. Banfield C, O’Reilly R, Chan E, Rowland M. Phenylbutazone-
warfarin interaction in man: further stereochemical and
metabolic considerations. Br
16:669–75.
J Clin Pharmacol 1983;
16. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E,
Begaud B, Dequeker J, Isomaki H, Littlejohn G, Mau J,
Papazoglou S. Gastrointestinal tolerability of meloxicam
33. Savitsky JP, Terzakis T, Bina P, Chiccarelli F, Haynes J.
Fenbufen-warfarin interaction in healthy volunteers
(abstract). Clin Pharmacol Ther 1980; 27:284.
compared to diclofenac in osteoarthritis patients. Br
Rheumatol 1998; 37:937–45.
J
34. Farnham DJ. Studies of isoxicam in combination with aspirin,
warfarin sodium and cimetidine. Semin Arthr Rheum 1982;
12(Suppl.):179–83.
17. Knijff-Dutmer EAJ, Martens A, vd Laar MAFJ. The effect of
nabumetone versus naproxen on platelet aggregation in
patients with rheumatoid arthritis. Ann Rheum Dis 1999;
58:257–9.
35. Slattery JT, Levy G, Jain A, McMahon FG. Effect of naproxen
on the kinetics of elimination and anticoagulant activity
of a single dose of warfarin. Clin Pharmacol Ther 1979; 25:
51–60.
18. Knijff-Dutmer EAJ, Kalsbeek-Batenburg EM, Koerts J, vd Laar
MAFJ. Platelet function is inhibited by non-selective Non
Steroidal Anti-Inflammatory Drugs but not by COX-2
selective inhibitors in patients with rheumatoid arthritis.
Rheumatol 2002; 41:458–61.
36. Hecken van A, Schwartz JI, Depre M, De Lepeire I, Dallob A,
Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel
DL, Gertz BJ, De Schepper PJ. Comparative inhibitory
activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and